Skip to main content

CorMedix Inc.

corporate_fare Company Profile

CorMedix Inc.

CRMD·NASDAQ·Life Sciences·CIK 0001410098

CorMedix Inc. is a biopharmaceutical company that develops and sells therapeutic products for life-threatening diseases and conditions. The company's main focus has been the commercialization of DefenCath® (taurolidine and heparin) in the U.S., which it launched in 2024 for use in hemodialysis. On August 29, 2025, CorMedix Inc. acquired Melinta Therapeutics, LLC, expanding its team and commercial platform. This acquisition increased the company's commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products: REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection ("MINOCIN IV"), VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), and BAXDELA® (delafloxacin). The acquisition also included TOPROL-XL® (metoprolol succinate), a cardiovascular product. The Melinta Portfolio supports a multi-channel strategy for delivering anti-infectives for serious gram-positive, gram-negative, and fungal infections within hospitals and the hospital ecosystem, including emergency departments, outpatient clinics, and home infusion care. The company's corporate strategy focuses on maximizing the value of its current portfolio, with promotional efforts concentrated on DefenCath, REZZAYO, MINOCIN IV, and VABOMERE.

CorMedix Inc. (NASDAQ:CRMD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CRMD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • CorMedix Finalizes Annual Meeting Proposals, Seeks Shareholder Vote on Key Governance Changes and Preferred Stock Amendment Ratification
  • CorMedix Announces Positive Phase III Results for REZZAYO, Meeting Primary Endpoint for Fungal Prophylaxis
  • CorMedix's REZZAYO Phase III Trial Hits Primary Endpoint for Fungal Prophylaxis, Targets $2B Market Expansion
  • CorMedix Seeks Shareholder Approval for Key Governance Changes, Including Ratification of Past Preferred Stock Amendments and Officer Liability Limits
  • CorMedix Clarifies FY27 DefenCath Sales Guidance Upward After Earnings Call Misstatement

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$311.71M
Net Income
$163.06M
Diluted EPS
$2.04
Op. Cash Flow
$175.05M
Free Cash Flow
$172.79M
Gross Profit
$275.75M
Operating Income
$150.14M
Cash & Equivalents
$144.84M
Debt / Equity
0.00×
Net Margin
52.3%
Shares Outstanding
79.26M sh
Source: 10-K · filed 2026-03-05 · accession 0001213900-26-023889
$5.32 +0.95% today
52-week range · as of 2026-11-16 $4.65 – $13.02
Market cap
$419.16M
Volume
3.6M (1.8× avg)
3-mo avg 2M
Live data · 2026-11-22 06:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRMD - Filings & News (Page 2)

CRMD
Apr 29, 2026, 4:16 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $7.48
Real-time Price: $5.32 info
Change: -$2.16 (-29%) info
Market Cap: $419.163M info
CRMD
Apr 27, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.47
Real-time Price: $5.32 info
Change: -$2.14 (-29%) info
Market Cap: $419.163M info
CRMD
Apr 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.47
Real-time Price: $5.32 info
Change: -$2.15 (-29%) info
Market Cap: $419.163M info
CRMD
Apr 17, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $7.39
Real-time Price: $5.32 info
Change: -$2.07 (-28%) info
Market Cap: $419.163M info
CRMD
Mar 06, 2026, 5:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.37
Real-time Price: $5.32 info
Change: -$1.05 (-16%) info
Market Cap: $419.163M info
CRMD
Mar 05, 2026, 8:32 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $6.75
Real-time Price: $5.32 info
Change: -$1.43 (-21%) info
Market Cap: $419.163M info
CRMD
Mar 05, 2026, 7:47 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.75
Real-time Price: $5.32 info
Change: -$1.43 (-21%) info
Market Cap: $419.163M info
CRMD
Mar 05, 2026, 7:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.74
Real-time Price: $5.32 info
Change: -$1.42 (-21%) info
Market Cap: $419.163M info
CRMD
Jan 08, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.80
Real-time Price: $5.32 info
Change: -$5.48 (-51%) info
Market Cap: $419.163M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets